Cyclerion Therapeutics, Inc. (CYCN)
CYCN Stock Price Chart
Explore Cyclerion Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CYCN price movements and trends.
CYCN Company Profile
Discover essential business fundamentals and corporate details for Cyclerion Therapeutics, Inc. (CYCN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Mar 2019
Employees
1.00
Website
https://www.cyclerion.comCEO
Regina Graul
Description
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier. It is presently in Phase IIa clinical assessments for managing mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as Alzheimer's disease with vascular involvement. Concurrently, CY6463 is undergoing Phase 1 trials for treating schizophrenia in adult populations. The company's research portfolio also features other promising candidates: Praliciguat, an orally administered systemic sGC stimulator, is in Phase II studies targeting resistant hypertension and diabetic nephropathy. Olinciguat, another sGC stimulator designed for oral intake with a vascular focus, is progressing through Phase II trials for sickle cell disease. Moreover, CY3018 is under development to address a range of CNS ailments. Cyclerion holds a licensing agreement with Akebia Therapeutics, Inc., covering the entire lifecycle from development and manufacturing to medical affairs and commercialization for certain pharmaceutical compounds and related products. The company was founded in 2018 and has its principal place of business in Cambridge, Massachusetts.
CYCN Financial Timeline
Browse a chronological timeline of Cyclerion Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$7.10, while revenue estimate is $1.50m.
Earnings released on 15 May 2026
Earnings released on 12 May 2026
EPS came in at -$0.76 surpassing the estimated -$17.20 by +95.58%.
Earnings released on 30 Mar 2026
EPS came in at -$0.19 surpassing the estimated -$0.38 by +50.00%, while revenue for the quarter reached $1.03m , beating expectations by +925.00%.
Earnings released on 25 Mar 2026
EPS came in at -$0.38 matching the estimated -$0.38, while revenue for the quarter reached $100.00k , meeting expectations.
Earnings released on 12 Nov 2025
EPS came in at -$0.30 , while revenue for the quarter reached $875.00k .
Earnings released on 5 Aug 2025
EPS came in at -$0.11 , while revenue for the quarter reached $93.00k .
Earnings released on 6 May 2025
EPS came in at -$0.56 , while revenue for the quarter reached $81.00k .
Earnings released on 4 Mar 2025
EPS came in at $0.22 , while revenue for the quarter reached $1.81m .
Earnings released on 14 Nov 2024
EPS came in at -$0.29 , while revenue for the quarter reached $194.00k .
Earnings released on 5 Mar 2024
EPS came in at -$0.68 surpassing the estimated -$7.40 by +90.75%.
Earnings released on 13 Nov 2023
EPS came in at -$0.93 surpassing the estimated -$6.40 by +85.47%.
Earnings released on 28 Jul 2023
EPS came in at -$1.83 surpassing the estimated -$5.60 by +67.32%.
Stock split effective on 16 May 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 May 2023
EPS came in at -$3.20 surpassing the estimated -$6.00 by +46.67%.
Earnings released on 22 Mar 2023
EPS came in at -$3.20 surpassing the estimated -$5.80 by +44.83%, while revenue for the quarter reached $1.63m , beating expectations by +167.27%.
Earnings released on 3 Nov 2022
EPS came in at -$4.80 surpassing the estimated -$7.00 by +31.43%.
Earnings released on 9 Aug 2022
EPS came in at -$6.20 surpassing the estimated -$6.80 by +8.82%, while revenue for the quarter reached $72.00k , missing expectations by -79.75%.
Earnings released on 4 May 2022
EPS came in at -$6.00 surpassing the estimated -$7.20 by +16.67%, while revenue for the quarter reached $225.00k , missing expectations by -59.09%.
Earnings released on 24 Feb 2022
EPS came in at -$4.80 surpassing the estimated -$6.40 by +25.00%, while revenue for the quarter reached $182.00k , missing expectations by -79.78%.
Earnings released on 9 Nov 2021
EPS came in at -$5.20 surpassing the estimated -$5.80 by +10.34%, while revenue for the quarter reached $77.00k , missing expectations by -79.95%.
Earnings released on 29 Jul 2021
EPS came in at -$9.00 , while revenue for the quarter reached $3.00m .
CYCN Stock Performance
Access detailed CYCN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
